Get regular updates to your inbox.
Peritoneal dialysis (PD), a blood filtration procedure that can be done at home, has been used successfully over a long period to manage kidney failure caused by diabetes in a patient with Prader-Willi syndrome, a case report shows. This approach may…
A new study described a rare case of a young man with Prader-Willi syndrome (PWS) with an invasive infection of the ear canal and the skull base who was successfully treated with antibiotics. The research, “Malignant otitis externa in a 21-year-old male patient with Prader-Willi syndrome,” was…
A case report suggested that treatment with denosumab (commercial names: Prolia, Xgeva) could be effective for patients with Prader-Willi syndrome (PWS), osteoporosis, and a history of fractures. The case was reported in the journal Therapeutics and Clinical Risk Management, in an article titled “Efficacy of Denosumab Therapy for a…
UConn Health and the Foundation for Prader-Willi Research (FPWR) announced the creation of a centralized biobank to provide researchers worldwide with high-quality, validated stem cells for in-depth studies about the causes of PWS and possible treatments. Stem cells can differentiate into other types of cells, such as brain,…
A new blood test called EpiSign may help identify complex and hard-to-diagnose genomic imprinting disorders such as Prader-Willi syndrome (PWS). EpiSign, available in two versions, can diagnose 19 complex disorders. This newly available diagnostic tool, which identifies common DNA modifications, may also help researchers understand the clinical significance of genetic…
Treatment with an Indian cactus extract reduces appetite in a mouse model of Prader-Willi syndrome (PWS) by interfering with a serotonin receptor in the animal’s brain, a study reports. The study, “Caralluma fimbriata extract activity involves the 5‐HT2c receptor in PWS Snord116 deletion mouse model,” was published in the journal …
A compound that could mimic ghrelin hormone activity and trigger its receptor signals could hold therapeutic potential to improve survival of patients with Prader-Willi syndrome (PWS) in early infancy, a mouse study shows. The study, “Ghrelin Receptor Agonist Rescues Excess…
Millendo Therapeutics has launched a Phase 2b/3 clinical trial investigating the safety and efficacy of livoletide (AZP-531) in patients with Prader-Willi syndrome (PWS), the company announced. The rare genetic disease is characterized by hyperphagia (excessive eating) and obesity, caused by abnormal hormonal levels. Livoletide is designed to reduce…
The Data Safety Monitoring Board recommended the continuation of Soleno Therapeutics’ Phase 3 clinical trial evaluating the effects of diazoxide choline controlled release (DCCR) treatment in children and adults with Prader-Willi syndrome (PWS), the company announced. Hyperphagia (excessive eating) is a classic PWS symptom caused by hormonal or…
Preclinical studies on the long-term impact of the investigational therapy ZGN-1258, being developed as a potential therapy for Prader-Willi syndrome (PWS), revealed alarming toxicity events and safety issues, Zafgen, the therapy’s developer, has announced. Based on these negative results, the company has changed its plans for ZGN-1258,…
Get regular updates to your inbox.